Madison Square Garden Sports Corp. heads into this week with a quietly building short position and a freshly downgraded Citi rating — a pairing that deserves attention even as the stock holds near its year-to-date highs.
Short sellers have been adding pressure steadily over the past six weeks. SI % FF has climbed from roughly 4.6% in early April to 5.76% by May 12 — a 25% increase in reported short shares over the past month. The move has been grinding rather than dramatic: positions built through April's volatility, paused briefly around May 7-8, then resumed. Days to cover is 2.9, so there's no acute squeeze setup here. What's notable is the direction — shorts have consistently added through a period when the stock is up more than 33% year-to-date and closed the week at $336.12.
The lending market does not signal any stress on the borrow side. Cost to borrow eased to just 0.46%, down roughly 10% over the past week and the lowest level in the 30-day window. Borrowing MSGS is cheap and uncrowded. Availability is ample relative to the short position — the borrow pool is far from being exhausted. Options positioning edged slightly more cautious on the week, with the put/call ratio ticking up to 0.74 versus a 20-day average of 0.68. That's less than one standard deviation above normal, so it registers as mild rather than alarmed.
The analyst picture is where the week's most interesting signal sits. Citi's Jason Bazinet downgraded MSGS to Neutral from Buy on April 23 — raising the target to $355 at the same time — and followed that up on May 13 with another nudge higher to $360, still at Neutral. That pattern — upgrading the price target while stepping to the sidelines on rating — implies the fundamental story is improving but the valuation gap has narrowed. Guggenheim pushed its Buy target to $401 in late April, and Seaport Global upgraded to Buy with a $430 target in early April. Susquehanna is at $388 with a Positive rating. The mean target across the Street is $379, roughly 13% above the current price. That consensus upside is real, but the mix of ratings has shifted more cautious: Citi's downgrade is the headline move, and the stock's 33% YTD run is a plausible explanation for why.
Valuation underlines the complexity here. MSGS carries an EV/EBITDA of around 491x on the latest reading — a number that reflects the well-known difficulty of valuing a franchise-heavy sports business on conventional multiples. The bull case rests on asset separation potential and the NBA's possible expansion into Las Vegas, Seattle, and Europe, each of which would materially re-rate the embedded franchise values. The bear case is simpler: a controlled company run by the Dolan family, negative book value, and a stock that has already priced in considerable optimism. EPS momentum stands in the 99th percentile over 30 days, which means earnings estimates have been rising sharply — yet the EPS surprise factor sits at just the 8th percentile, a reminder that actual results have historically disappointed relative to expectations.
On the institutional side, T. Rowe Price is the standout recent mover, adding 331,730 shares as of March 31 to bring its stake to 5.6% of shares outstanding. BlackRock added modestly too. The Dolan family trust trimmed slightly in late February, selling just over 37,000 shares — a small reduction against a nearly 20% ownership stake. The most recent insider open-market sale was also in February, when Charles Dolan sold roughly 5,600 shares around $325-327. At today's $336 level, those sales look tactically well-timed.
The next earnings event isn't until August 12. With borrow cheap, positions building slowly, options only mildly defensive, and Citi content to sit at Neutral even as it marks the target higher, the conversation between now and then will centre on whether the NBA expansion narrative adds enough fundamental re-rating to justify a stock already up a third on the year.
See the live data behind this article on ORTEX.
Open MSGS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
